Gottschalk B, Wiesemann H G, Stephan U
Klinik und Poliklinik für Kinder, Universität (GHS) Essen.
Monatsschr Kinderheilkd. 1988 Sep;136(9):626-9.
In an open trial 10 patients with cystic fibrosis were treated with two acid-protected pancreatic enzyme preparations formed as microtablets or pellets. The difference between Panzytrat 20,000 and Kreon is that with only 225 mg pancreatin, the former has twice the lipase activity of the latter. Therefore, the patients who had been taken Kreon were given only half the number of Panzytrat 20,000 capsules. There were no significant differences seen between the amounts of fecal fat nor in the fecal weight. In our study the fat absorption coefficient was somewhat too low with 67.4% for Kreon and 71.3% for Panzytrat 20,000 because of too low enzyme dosage, which was based only on an improvement of the clinical symptoms. Therefore, we would recommend a higher dose of 1000-1500 units of lipase/l g of dietary fat ingested. This requires the use of a preparation with high enzyme activity.
在一项开放性试验中，10名囊性纤维化患者接受了两种制成微片或小丸的耐酸型胰酶制剂治疗。泮托拉唑20000与慷彼申的区别在于，前者仅含225毫克胰酶，但其脂肪酶活性却是后者的两倍。因此，服用慷彼申的患者服用泮托拉唑20000胶囊的数量仅为一半。粪便脂肪量和粪便重量方面均未观察到显著差异。在我们的研究中，由于酶剂量过低（仅基于临床症状的改善），慷彼申的脂肪吸收系数为67.4%，泮托拉唑20000的脂肪吸收系数为71.3%，均有点过低。因此，我们建议每摄入1克膳食脂肪使用1000 - 1500单位脂肪酶的更高剂量。这需要使用具有高酶活性的制剂。
